SRF Limited’s board has approved a revised capital expenditure proposal for setting up a facility dedicated to the production of specialty fluoropolymers. This decision follows strategic agreements with The Chemours Company for manufacturing, supply, and distribution partnerships. The revised capex aims to meet customer demand, with the facility expected to be operational by December 2026 and requiring an investment of Rs. 745 Crores.
Revised Capex Approved
The Board of SRF Limited has given its approval for a revised capital expenditure (capex) related to the establishment of a production facility for a range of specialty fluoropolymers. This decision, made on October 27, 2025, follows previously announced plans and reflects strategic adjustments to the project’s scope.
Strategic Agreements and Rationale
This revised capex decision is linked to strategic agreements negotiated with The Chemours Company. These agreements focus on partnership for manufacturing, supply, and distribution of certain fluoropolymers and fluoroelastomers. The company aims to address and meet the customer demand with this facility.
Project Details and Timeline
The revised capex involves an investment of Rs. 745 Crores. The funding will be achieved through a mix of debt and internal accruals. The company anticipates that the facility will be operational by December 2026. The creation of a specialty fluoropolymers production facility reflects SRF’s ongoing strategic focus on high-value, specialized chemical products.
Source: BSE
